WOCKPHARMA.NS Cash Flow
Wockhardt Ltd.
Profit & Loss Balance Sheet Cash Flow
Cash Flow · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:46
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | ₹153.00 Cr. | ₹219.00 Cr. | ₹-22.00 Cr. | ₹390.00 Cr. | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹-125.00 Cr. | ₹-137.00 Cr. | ₹-783.00 Cr. | ₹-241.00 Cr. | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹-315.00 Cr. | ₹334.00 Cr. | ₹409.00 Cr. | ₹-54.00 Cr. | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹7.00 Cr. | ₹-1.00 Cr. | ₹3.00 Cr. | ₹10.00 Cr. | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹-280.00 Cr. | ₹415.00 Cr. | ₹-393.00 Cr. | ₹105.00 Cr. | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | ₹370.00 Cr. | ₹90.00 Cr. | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
Every figure above is the exact value of the named XBRL element from WOCKPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).